Skip to main content
. 2022 Mar 14;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246

Figure. Trends in Invasive Prostate Cancer: Surveillance, Epidemiology, and End Results 18 Registries 2004-2018 for All Races.

Figure.

The line segments of each curve were calculated with the Joinpoint Regression Analysis program. For each cohort, we compared the percentage difference in incidence rate (IR) between the lowest and the highest modeled value. Panel A shows data for derived SEER summary stage (distant); in men older than 75 years, the IR of metastatic prostate cancer (mPCa) increased by 43% from 2011 to 2018, from an annual percentage change (APC) of −1.5% to 6.5%, and in men aged 45 to 74, the IR of mPCa increased by 41% from 2010 to 2018, from an APC of −0.4% to 5.3%. Panel B shows data for derived American Joint Committee on Cancer (AJCC) M-stage (M1); in men older than 75 years, the IR of mPCa increased by 43% from 2010 to 2018, from an APC of −2.3% to 5.6%, and in men aged 45 to 74 years, the IR of mPCa increased by 39% from 2010 to 2018, from an APC of −0.1% to 5.1%. Panel C shows data for derived AJCC N-stage (N1); in men older than 75 years, the IR of N1 disease increased by 119% from 2004 to 2018, from an APC of 12.6% to 8.8%, and in men aged 45 to 74 years, the IR of N1 disease increased by 81% from 2004 to 2018, from an APC of 3.4% to 10.4%. Panel D shows data for derived AJCC T-stage (T3-T4); in men older than 75 years, the IR of T3-T4 disease increased by 45% from 2012 to 2018, from an APC of 2.3% to 7.9%, and in men aged 45 to 74 years, the IR of T3-T4 disease increased by 31% from 2013 to 2018, from an APC of −2.2% to 6.5%. Trends categorized by race are reported in eTable 1, eTable 2, and eTable 3 in the Supplement.